William Kiong-Seng Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
William Kiong-Seng Lim has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Richard Robert Neubig
Michigan State University
7 shared publications Mas Atikah Lizazman
3 shared publicationsNurr Maria Ulfa Seruji
3 shared publicationsPinFen Chua
Universiti Malaysia Sarawak
3 shared publications- Chang-Seon Myung
Department of Pharmacology, Chungnam National University College of Pharmacy, Daejeon, Republic of Korea
2 shared publications James C. Garrison
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in BMC Medical Education
A mobile app-based peer assessment for problem-based learning groups
- 24 August 2026
- Published by Springer Nature in BMC Medical Education
Open AccessA mobile app-based peer assessment for problem-based learning groups
- Open Access
- 1 December 2024
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 36 (11)
Advancing Parkinson’s disease biopathology and drug discovery by dual cellular modelling
- 1 December 2024
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 36 (11)
Open AccessAdvancing Parkinson’s disease biopathology and drug discovery by dual cellular modelling
- Open Access
- 21 November 2024
- Published by Springer Nature in Research Square
Advancing Parkinson’s Disease Biopathlogy and Drug Discovery by Dual Cellular Modeling
Parkinson’s disease (PD) is the fastest growing neurological disorder in the world. Its pathologic hallmarks are dopaminergic neuronal loss in the substantia nigra and alpha-synuclein accumulation in neurons. However the patho-biologic mechanisms are largely unknown. Current drugs cannot slow or halt disease progression while clinical trials are mostly unsuccessful. Hence better cellular models are needed for pathological and drug discovery studies prior to in vivo validation. PC12 cells are commonly used for neurotoxicity studies but the Neuroscreen-1 (NS-1) variant has a faster doubling time and higher basal rate of neurite growth. We developed a NS-1 PD model with the neurotoxin 6-hydroxydopamine (6-OHDA) and MTT cell viability assay as readout. We optimized 6-OHDA concentration to a uniquely low 10 µM for a closer approximation to in vivo neurotoxicity. NS-1 cells treated with 6-OHDA displayed hallmark dopamine loss and apoptotic cell death. We used the model to screen a series of xanthones - polyphenolic compounds found in many medicinal plants. We report a novel activity of thwaitesixanthone in the PD model. The model was validated using alpha-mangostin (a neuroprotectant in in vivo and in vitro PD models) which was the most active in restoring cell viability. Alpha-synuclein is now a therapeutic target for stopping PD progression. Human HEK293 cells have neuronal attributes and reported to express pathologic alpha-synuclein. We hypothesized the transfection-efficient HEK293T cells is an optimal cell line for monitoring human alpha-synuclein levels. We make the first report that 6-OHDA treatment increased pathologic alpha-synuclein expression in HEK293T cells. This alpha-synucleinopathy model was validated using alpha-mangostin which attenuated 6-OHDA-induced pathologic alpha-synuclein to baseline levels. Thus we developed a novel NS-1 PD model more representative of in vivo neurotoxicity complemented by a human HEK293T cell-based alpha-synucleinopathy model for tracking pathologic alpha-synuclein levels. We present these dual models for producing in vitro findings with increased likelihood of clinical translation.
- 21 November 2024
- Published by Springer Nature in Research Square
Open AccessAdvancing Parkinson’s Disease Biopathlogy and Drug Discovery by Dual Cellular Modeling
Parkinson’s disease (PD) is the fastest growing neurological disorder in the world. Its pathologic hallmarks are dopaminergic neuronal loss in the substantia nigra and alpha-synuclein accumulation in neurons. However the patho-biologic mechanisms are largely unknown. Current drugs cannot slow or halt disease progression while clinical trials are mostly unsuccessful. Hence better cellular models are needed for pathological and drug discovery studies prior to in vivo validation. PC12 cells are commonly used for neurotoxicity studies but the Neuroscreen-1 (NS-1) variant has a faster doubling time and higher basal rate of neurite growth. We developed a NS-1 PD model with the neurotoxin 6-hydroxydopamine (6-OHDA) and MTT cell viability assay as readout. We optimized 6-OHDA concentration to a uniquely low 10 µM for a closer approximation to in vivo neurotoxicity. NS-1 cells treated with 6-OHDA displayed hallmark dopamine loss and apoptotic cell death. We used the model to screen a series of xanthones - polyphenolic compounds found in many medicinal plants. We report a novel activity of thwaitesixanthone in the PD model. The model was validated using alpha-mangostin (a neuroprotectant in in vivo and in vitro PD models) which was the most active in restoring cell viability. Alpha-synuclein is now a therapeutic target for stopping PD progression. Human HEK293 cells have neuronal attributes and reported to express pathologic alpha-synuclein. We hypothesized the transfection-efficient HEK293T cells is an optimal cell line for monitoring human alpha-synuclein levels. We make the first report that 6-OHDA treatment increased pathologic alpha-synuclein expression in HEK293T cells. This alpha-synucleinopathy model was validated using alpha-mangostin which attenuated 6-OHDA-induced pathologic alpha-synuclein to baseline levels. Thus we developed a novel NS-1 PD model more representative of in vivo neurotoxicity complemented by a human HEK293T cell-based alpha-synucleinopathy model for tracking pathologic alpha-synuclein levels. We present these dual models for producing in vitro findings with increased likelihood of clinical translation.
- Open Access
- 21 November 2024
- Published by Springer Nature in Research Square
Neuroscreen-1 Cell Line – a Model for Parkinson’s Disease Neuronal Cell Death but not Alpha-Synucleinopathy
Parkinson’s disease (PD) is characterised by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies containing α-synuclein (α-syn). PC12 cells are commonly used in cellular PD models. Neurocreen-1 cells (NS-1, a variant of PC12 cells) have a reduced doubling time and exhibit an enhanced neuronal phenotype compared to its parental PC12 cell line. This study aimed to develop a PD model with NS-1 cells based on the neurotoxin 6-hydroxydopamine (6-OHDA). Firstly, we investigated the expression of (endogenous) wild-type α-syn and pathological phosphorylated α-syn (pSer129-α-syn) in 6-OHDA-treated NS-1 cells via western blotting. However, wild type or pSer129-α-syn could not be immunodetected. Next, we examined the caspase-dependent apoptotic pathway in NS-1 cells treated with 6-OHDA. Cell viability was reduced, with significant activation of caspase-3 and -7. We validated this model by testing the effects of xanthones, a class of phytochemicals with reported neuroprotective properties. Gamma-mangostin at 10 nM increased cell viability with significant inhibition of caspase 3/7 activity, while beta-mangostin gave a lower effect. Lastly, we investigated the antiparkinsonian properties of lesser-studied xanthones: brasixanthone B, ananixanthone, thwaitesixanthone, trapezifolixanthone, and beta-mangostin. NS-1 cells replicated the effects of the neurotoxin 6-OHDA seen in parental PC12 cells. Of the lesser-studied xanthones, brasixanthone B and ananixanthone gave the greatest antiapoptotic activity in the PD model. We make the first report that brasixanthone B and thwaitesixanthone are neuroprotective. NS-1 is a fast-growing and adherent cell line with neuronal characteristics useful as an in vitro PD model in screening compounds for antiapoptotic effects, but unsuitable for modelling α-synucleinopathy.
- 21 November 2024
- Published by Springer Nature in Research Square
Open AccessNeuroscreen-1 Cell Line – a Model for Parkinson’s Disease Neuronal Cell Death but not Alpha-Synucleinopathy
Parkinson’s disease (PD) is characterised by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies containing α-synuclein (α-syn). PC12 cells are commonly used in cellular PD models. Neurocreen-1 cells (NS-1, a variant of PC12 cells) have a reduced doubling time and exhibit an enhanced neuronal phenotype compared to its parental PC12 cell line. This study aimed to develop a PD model with NS-1 cells based on the neurotoxin 6-hydroxydopamine (6-OHDA). Firstly, we investigated the expression of (endogenous) wild-type α-syn and pathological phosphorylated α-syn (pSer129-α-syn) in 6-OHDA-treated NS-1 cells via western blotting. However, wild type or pSer129-α-syn could not be immunodetected. Next, we examined the caspase-dependent apoptotic pathway in NS-1 cells treated with 6-OHDA. Cell viability was reduced, with significant activation of caspase-3 and -7. We validated this model by testing the effects of xanthones, a class of phytochemicals with reported neuroprotective properties. Gamma-mangostin at 10 nM increased cell viability with significant inhibition of caspase 3/7 activity, while beta-mangostin gave a lower effect. Lastly, we investigated the antiparkinsonian properties of lesser-studied xanthones: brasixanthone B, ananixanthone, thwaitesixanthone, trapezifolixanthone, and beta-mangostin. NS-1 cells replicated the effects of the neurotoxin 6-OHDA seen in parental PC12 cells. Of the lesser-studied xanthones, brasixanthone B and ananixanthone gave the greatest antiapoptotic activity in the PD model. We make the first report that brasixanthone B and thwaitesixanthone are neuroprotective. NS-1 is a fast-growing and adherent cell line with neuronal characteristics useful as an in vitro PD model in screening compounds for antiapoptotic effects, but unsuitable for modelling α-synucleinopathy.
- Open Access
- 1 December 2023
- Published by Taylor & Francis in Advances in Medical Education and Practice
- Vol. ume 14, 1453-1460
Problem Based Learning in Medical Education: Handling Objections and Sustainable Implementation
The introduction of problem-based learning (PBL) in 1969 is considered the greatest innovation in medical education of the past 50 years. Since then, PBL has been implemented in different educational settings across virtually all health professions. However, some PBL schools gradually faced resistance from academic staff who were more familiar with traditional teacher-centred curricula. At times this has resulted in reversion to tradition or compromise whereby PBL is implemented within a lecture-based curriculum. Resistance can also emerge in a traditional school when a PBL curriculum is being considered for implementation. One of the first signs of this erosion is doubts about PBL raised in the form of objections or criticisms. This perspective review describes eight objections raised to assert why PBL is inferior or untenable. The background to each objection is provided together with evidence-informed rebuttals derived from professional practice and the published literature. Best practices are discussed for sustainable management of a PBL-based curriculum. A well-implemented PBL curriculum with appropriate and cost-effective infrastructure, training, teaching-learning activities, and assessment will position schools to harness the full benefit of PBL in training medical and health professionals.
- 1 December 2023
- Published by Taylor & Francis in Advances in Medical Education and Practice
- Vol. ume 14, 1453-1460
Open AccessProblem Based Learning in Medical Education: Handling Objections and Sustainable Implementation
The introduction of problem-based learning (PBL) in 1969 is considered the greatest innovation in medical education of the past 50 years. Since then, PBL has been implemented in different educational settings across virtually all health professions. However, some PBL schools gradually faced resistance from academic staff who were more familiar with traditional teacher-centred curricula. At times this has resulted in reversion to tradition or compromise whereby PBL is implemented within a lecture-based curriculum. Resistance can also emerge in a traditional school when a PBL curriculum is being considered for implementation. One of the first signs of this erosion is doubts about PBL raised in the form of objections or criticisms. This perspective review describes eight objections raised to assert why PBL is inferior or untenable. The background to each objection is provided together with evidence-informed rebuttals derived from professional practice and the published literature. Best practices are discussed for sustainable management of a PBL-based curriculum. A well-implemented PBL curriculum with appropriate and cost-effective infrastructure, training, teaching-learning activities, and assessment will position schools to harness the full benefit of PBL in training medical and health professionals.
- Open Access
- 24 November 2022
- Published by Wiley in Cell Biology International
- Vol. 47 (2) , 367-373
The strategic uses of collagen in adherent cell cultures
The culture of adherent mammalian cells involves adhesion to the tissue culture vessel. This requires attachment factors from serum and/or a suitable substrate on the vessel surface. Some cells require collagen or other substrates to promote neurite outgrowth, differentiation or growth. However, laboratories often lack guidance on the selection and/or optimisation of collagen. We model such selection/optimisation work in the PC12 neuronal cell line. PC12 (NS‐1 variant) cells require a substrate for adherence. Comparing cell attachment against a series of substrates, we found collagen IV to be optimal. We show by comparison of morphology against a range of concentrations that 10 µg/ml is sufficient for supporting cell attachment, and also differentiation. PC12 cells from Riken Cell Bank do not require a substrate for routine culturing but only for differentiation. As all substrates supported attachment equally well, we used a novel serum‐free approach and identified collagen IV as its preferred substrate. For these cells, Dulbecco's modified eagle's medium but not Roswell Park Memorial Institute (RPMI) media supports normal cell attachment. However, coating with collagen IV enabled the cells to grow equally well in RPMI. Hence the strategic use of collagen is essential in laboratories working with anchorage‐dependent cell lines.
- 24 November 2022
- Published by Wiley in Cell Biology International
- Vol. 47 (2) , 367-373
Open AccessThe strategic uses of collagen in adherent cell cultures
The culture of adherent mammalian cells involves adhesion to the tissue culture vessel. This requires attachment factors from serum and/or a suitable substrate on the vessel surface. Some cells require collagen or other substrates to promote neurite outgrowth, differentiation or growth. However, laboratories often lack guidance on the selection and/or optimisation of collagen. We model such selection/optimisation work in the PC12 neuronal cell line. PC12 (NS‐1 variant) cells require a substrate for adherence. Comparing cell attachment against a series of substrates, we found collagen IV to be optimal. We show by comparison of morphology against a range of concentrations that 10 µg/ml is sufficient for supporting cell attachment, and also differentiation. PC12 cells from Riken Cell Bank do not require a substrate for routine culturing but only for differentiation. As all substrates supported attachment equally well, we used a novel serum‐free approach and identified collagen IV as its preferred substrate. For these cells, Dulbecco's modified eagle's medium but not Roswell Park Memorial Institute (RPMI) media supports normal cell attachment. However, coating with collagen IV enabled the cells to grow equally well in RPMI. Hence the strategic use of collagen is essential in laboratories working with anchorage‐dependent cell lines.
- Open Access
- 14 April 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents
Stroke causes death and disability globally but no neuroprotectant is approved for post-stroke neuronal injury. Neuroprotective compounds can be identified using oxygen glucose deprivation (OGD) of neuronal cells as an in vitro stroke model. Nerve growth factor (NGF)-differentiated PC12 pheochromocytoma cells are frequently used. However, investigators often find their clonal variant undifferentiable and are uncertain of optimal culture conditions. Hence we studied 3 commonly used PC12 variants: PC12 Adh, PC12 from Riken Cell Bank (PC12 Riken) and Neuroscreen-1 (NS-1) cells. We found DMEM the optimal media for PC12 Riken and NS-1 cells. Using a novel serum-free media approach, we identified collagen IV as the preferred adhesive substrate for both cell lines. We found PC12 Adh cells cannot attach without serum and is unable to differentiate using NGF. NS-1 cells differentiated to a maximal 72.7 ± 5.2% %, with substantial basal differentiation. We optimised differentiated NS-1 cells for an in vitro stroke model using 3 h of OGD resulting in ~ 70% viable cells. We screened 5 reported neuroprotectants and provide the first report that serotonin is antiapoptotic in a stroke model and the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) is neuroprotective in PC12 cells. Thus we demonstrate the optimisation and validation for a PC12 cell-based in vitro stroke model.
- 14 April 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Open AccessOptimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents
Stroke causes death and disability globally but no neuroprotectant is approved for post-stroke neuronal injury. Neuroprotective compounds can be identified using oxygen glucose deprivation (OGD) of neuronal cells as an in vitro stroke model. Nerve growth factor (NGF)-differentiated PC12 pheochromocytoma cells are frequently used. However, investigators often find their clonal variant undifferentiable and are uncertain of optimal culture conditions. Hence we studied 3 commonly used PC12 variants: PC12 Adh, PC12 from Riken Cell Bank (PC12 Riken) and Neuroscreen-1 (NS-1) cells. We found DMEM the optimal media for PC12 Riken and NS-1 cells. Using a novel serum-free media approach, we identified collagen IV as the preferred adhesive substrate for both cell lines. We found PC12 Adh cells cannot attach without serum and is unable to differentiate using NGF. NS-1 cells differentiated to a maximal 72.7 ± 5.2% %, with substantial basal differentiation. We optimised differentiated NS-1 cells for an in vitro stroke model using 3 h of OGD resulting in ~ 70% viable cells. We screened 5 reported neuroprotectants and provide the first report that serotonin is antiapoptotic in a stroke model and the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) is neuroprotective in PC12 cells. Thus we demonstrate the optimisation and validation for a PC12 cell-based in vitro stroke model.
- Open Access
- 28 January 2021
- Published by Springer Nature in Chinese Medicine
- Vol. 16 (1) , 1-22
Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review
Background: Hereditary ataxia (HA) represents a group of genetically heterogeneous neurodegenerative diseases caused by dysfunction of the cerebellum or disruption of the connection between the cerebellum and other areas of the central nervous system. Phenotypic manifestation of HA includes unsteadiness of stance and gait, dysarthria, nystagmus, dysmetria and complaints of clumsiness. There are no specific treatments for HA. Management strategies provide supportive treatment to reduce symptoms. Objectives: This systematic review aimed to identify, evaluate and summarise the published literature on the therapeutic roles of natural remedies in the treatment of HA to provide evidence for clinical practice. Methods: A systematic literature search was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Web of Science, PubMed and Science Direct Scopus were thoroughly searched for relevant published articles from June 2007 to July 2020. Results: Ten pre-clinical and two clinical studies were eligible for inclusion in this systematic review. We identified the therapeutic roles of medicinal plants Brassica napus, Gardenia jasminoides, Gastrodia elata, Ginkgo biloba, Glycyrrhiza inflata, Paeonia lactiflora, Pueraria lobata and Rehmannia glutinosa; herbal formulations Shaoyao Gancao Tang and Zhengan Xifeng Tang; and medicinal mushroom Hericium erinaceus in the treatment of HA. In this review, we evaluated the mode of actions contributing to their therapeutic effects, including activation of the ubiquitin–proteasome system, activation of antioxidant pathways, maintenance of intracellular calcium homeostasis and regulation of chaperones. We also briefly highlighted the integral cellular signalling pathways responsible for orchestrating the mode of actions. Conclusion: We reviewed the therapeutic roles of natural remedies in improving or halting the progression of HA, which warrant further study for applications into clinical practice.
- 28 January 2021
- Published by Springer Nature in Chinese Medicine
- Vol. 16 (1) , 1-22
Open AccessTherapeutic roles of natural remedies in combating hereditary ataxia: A systematic review
Background: Hereditary ataxia (HA) represents a group of genetically heterogeneous neurodegenerative diseases caused by dysfunction of the cerebellum or disruption of the connection between the cerebellum and other areas of the central nervous system. Phenotypic manifestation of HA includes unsteadiness of stance and gait, dysarthria, nystagmus, dysmetria and complaints of clumsiness. There are no specific treatments for HA. Management strategies provide supportive treatment to reduce symptoms. Objectives: This systematic review aimed to identify, evaluate and summarise the published literature on the therapeutic roles of natural remedies in the treatment of HA to provide evidence for clinical practice. Methods: A systematic literature search was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Web of Science, PubMed and Science Direct Scopus were thoroughly searched for relevant published articles from June 2007 to July 2020. Results: Ten pre-clinical and two clinical studies were eligible for inclusion in this systematic review. We identified the therapeutic roles of medicinal plants Brassica napus, Gardenia jasminoides, Gastrodia elata, Ginkgo biloba, Glycyrrhiza inflata, Paeonia lactiflora, Pueraria lobata and Rehmannia glutinosa; herbal formulations Shaoyao Gancao Tang and Zhengan Xifeng Tang; and medicinal mushroom Hericium erinaceus in the treatment of HA. In this review, we evaluated the mode of actions contributing to their therapeutic effects, including activation of the ubiquitin–proteasome system, activation of antioxidant pathways, maintenance of intracellular calcium homeostasis and regulation of chaperones. We also briefly highlighted the integral cellular signalling pathways responsible for orchestrating the mode of actions. Conclusion: We reviewed the therapeutic roles of natural remedies in improving or halting the progression of HA, which warrant further study for applications into clinical practice.
- 1 February 2013
- Published by Elsevier in Cellular Signalling
- Vol. 25 (2) , 389-396
Regulation of G protein signaling by the 70kDa heat shock protein
- 1 February 2013
- Published by Elsevier in Cellular Signalling
- Vol. 25 (2) , 389-396
Regulation of G protein signaling by the 70kDa heat shock protein
- Open Access
- 25 September 2012
- Published by Springer Nature in BMC Medical Education
- Vol. 12 (1) , 89
Dysfunctional problem-based learning curricula: resolving the problem
Problem-based learning (PBL) has become the most significant innovation in medical education of the past 40 years. In contrast to exam-centered, lecture-based conventional curricula, PBL is a comprehensive curricular strategy that fosters student-centred learning and the skills desired in physicians. The rapid spread of PBL has produced many variants. One of the most common is 'hybrid PBL' where conventional teaching methods are implemented alongside PBL. This paper contends that the mixing of these two opposing educational philosophies can undermine PBL and nullify its positive benefits. Schools using hybrid PBL and lacking medical education expertise may end up with a dysfunctional curriculum worse off than the traditional approach.
- 25 September 2012
- Published by Springer Nature in BMC Medical Education
- Vol. 12 (1) , 89
Open AccessDysfunctional problem-based learning curricula: resolving the problem
Problem-based learning (PBL) has become the most significant innovation in medical education of the past 40 years. In contrast to exam-centered, lecture-based conventional curricula, PBL is a comprehensive curricular strategy that fosters student-centred learning and the skills desired in physicians. The rapid spread of PBL has produced many variants. One of the most common is 'hybrid PBL' where conventional teaching methods are implemented alongside PBL. This paper contends that the mixing of these two opposing educational philosophies can undermine PBL and nullify its positive benefits. Schools using hybrid PBL and lacking medical education expertise may end up with a dysfunctional curriculum worse off than the traditional approach.